The efficacy and safety of rifaximin-α: a 2-year observational study of overt hepatic encephalopathy

BACKGROUND: After 5  years since the registration of rifaximin-α as a secondary prophylaxis for overt hepatic encephalopathy (HE) in the Netherlands, we aimed to evaluate the use of hospital resources and safety of rifaximin-α treatment in a real-world setting. METHODS: We carried out prospective id...

Descripción completa

Detalles Bibliográficos
Autores principales: Oey, Rosalie C., Buck, Lennart E.M., Erler, Nicole S., van Buuren, Henk R., de Man, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591657/
https://www.ncbi.nlm.nih.gov/pubmed/31258622
http://dx.doi.org/10.1177/1756284819858256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591657/
https://www.ncbi.nlm.nih.gov/pubmed/31258622
http://dx.doi.org/10.1177/1756284819858256

Ejemplares similares